Amneal Pharmaceuticals マネジメント
マネジメント 基準チェック /34
Amneal Pharmaceuticalsの CEO はChirag Patelで、 Jan2005年に任命され、 の在任期間は 21.58年です。 の年間総報酬は$ 8.69Mで、 9.2%給与と90.8%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の7.1%を直接所有しており、その価値は$ 418.36M 。経営陣と取締役会の平均在任期間はそれぞれ7.1年と7.6年です。
主要情報
Chirag Patel
最高経営責任者
US$8.7m
報酬総額
| CEO給与比率 | 9.20% |
| CEO在任期間 | 21.6yrs |
| CEOの所有権 | 7.1% |
| 経営陣の平均在職期間 | 7.1yrs |
| 取締役会の平均在任期間 | 7.6yrs |
経営陣の近況
Recent updates
分析記事 • 5h
Amneal Pharmaceuticals' (NASDAQ:AMRX) Strong Earnings Are Of Good Quality
Amneal Pharmaceuticals, Inc. ( NASDAQ:AMRX ) just reported healthy earnings but the stock price didn't move much...
ナラティブ更新 • Aug 01
AMRX: Crexont And Biosimilars Will Test Fairly Valued 2026 Outlook
Analysts have lifted their fair value estimate for Amneal Pharmaceuticals by $2.00 to $20.25, citing updated assumptions on revenue growth, profit margins, and future P/E that reflect recent price target increases related to Crexont, Women's Health, and biosimilar progress. Analyst Commentary Recent commentary on Amneal Pharmaceuticals focuses on how key growth drivers and execution on upcoming launches could influence valuation over the next few years.
新しいナラティブ • Aug 01
Biosimilars And GLP-1 Expansion Will Expose Mounting Operational And Execution Risks
Catalysts About Amneal Pharmaceuticals Amneal Pharmaceuticals develops, manufactures and markets affordable medicines across generics, biosimilars and specialty products in the United States and selected global markets. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Jul 20
Amneal: Kashiv Deal Fuels Biosimilar Growth, But Stock Already Prices In Optimism
Summary Amneal Pharmaceuticals has diversified beyond generics, driving margin expansion and improved financial health, but now trades near all-time highs. AMRX’s growth hinges on the Kashiv BioSciences acquisition, which is expected to add biosimilars and support management’s $4.25 billion 2030 revenue target. Despite improved operating leverage and reaffirmed 2026 guidance, persistent debt, settlement costs, and dilution from acquisitions cap free cash flow potential. My DCF analysis suggests AMRX is fully valued for management’s bullish projections; I maintain a neutral/Hold rating given limited upside and execution risks. Read the full article on Seeking Alpha
新しいナラティブ • Jul 17
Biosimilars Expansion And Vertical Integration Will Reshape Long-Term Outlook
Catalysts About Amneal Pharmaceuticals Amneal Pharmaceuticals focuses on affordable medicines across generics, specialty drugs and biosimilars, with a growing presence in large molecule therapies. What are the underlying business or industry changes driving this perspective?ナラティブ更新 • Jul 15
AMRX: Biosimilars And 2026 Execution Will Shape Fairly Valued Outlook
Analysts have raised their fair value estimate for Amneal Pharmaceuticals by $1 to $18.25, citing higher price targets from recent research, confidence in growth from Crexont, Women's Health and biosimilars, and support from improving expectations reflected in a modestly higher assumed future P/E multiple. Analyst Commentary Recent Street research on Amneal Pharmaceuticals highlights a mix of enthusiasm around growth drivers like Crexont, Women's Health and biosimilars, alongside a few areas where execution and valuation expectations could face tests.分析記事 • Jun 21
Amneal Pharmaceuticals (AMRX) Stock Could Be 6% Below Fair Value After Its Sharp Rally
Why Amneal Pharmaceuticals Stock Is On Investors’ Radar Amneal Pharmaceuticals (AMRX) has been drawing attention after a strong share price move over the past month and past 3 months, prompting investors to reassess what the current valuation implies. The stock recently closed at US$16.21, and available data shows it trades at a discount to one independent intrinsic value estimate. This may interest readers comparing Amneal to other US biopharmaceutical companies. See our latest analysis for...ナラティブ更新 • Jun 19
AMRX: Biosimilar Buildout And 2026 Execution Will Shape Fairly Valued Stock
Analysts have nudged their fair value estimate for Amneal Pharmaceuticals up to $17.25 from $17.20, citing higher projected profit margins and renewed confidence in the 2026 outlook as the company works to narrow its valuation gap with peers and advance its biosimilar efforts. Analyst Commentary Recent research on Amneal Pharmaceuticals highlights a mix of optimism on the 2026 setup and some areas where investors may want to stay disciplined on execution and valuation.ナラティブ更新 • Jun 04
AMRX: Biosimilar Execution And 2026 Outlook Will Support Share Rebound
Analysts have inched their fair value estimate for Amneal Pharmaceuticals up from $17.00 to $17.20 and raised the price target to $16.00, citing stronger confidence in the fiscal 2026 outlook, a solid Q1 update, and an increasing focus on biosimilar opportunities compared with peers. Analyst Commentary Bullish Takeaways Bullish analysts point to the recent Q1 report as a key support for their higher fair value estimates, viewing the current execution as consistent with their fiscal 2026 expectations.ナラティブ更新 • May 04
AMRX: 2026 EBITDA Outlook Will Support Rebound After GRx Driven Pullback
Amneal Pharmaceuticals' consensus analyst price target has shifted to $17.00, with analysts citing solid Q4 results, strengthened FY26 EBITDA guidance and a reset future P/E assumption as support for this updated view. Analyst Commentary Recent research has focused on how Amneal Pharmaceuticals' updated FY26 guidance and Q4 performance feed into valuation, growth expectations and execution risk around that new US$17.00 price target.ナラティブ更新 • Apr 19
AMRX: 2026 EBITDA Plan And Inhalation Entry Will Drive Bullish Setup
Amneal Pharmaceuticals' analyst price target has shifted from $16.80 to about $17.17, with analysts pointing to recent target increases to $17 following solid Q4 results, 2026 EBITDA guidance strength, and a still intact long term growth thesis as key support for the updated view. Analyst Commentary Recent Street research around Amneal Pharmaceuticals has been concentrated on Q4 results, the new 2026 outlook, and how these feed into revised targets near $17.ナラティブ更新 • Apr 02
AMRX: 2026 EBITDA Plan And Affordable Medicines Theme Will Drive Bullish Setup
Analysts have raised their price targets on Amneal Pharmaceuticals from $15 to $17, citing solid Q4 results, 2026 guidance that highlights stronger EBITDA expectations, and continued interest in the affordable medicines theme as key supports for the updated view. Analyst Commentary Analysts raising targets to $17 are largely focused on how Amneal executes against its 2026 plan and how that ties into the affordable medicines theme and EBITDA outlook.ナラティブ更新 • Mar 18
AMRX: 2026 EBITDA Guidance Will Shape Bullish Setup Despite Recent Pullback
Narrative Update on Amneal Pharmaceuticals The analyst price target for Amneal Pharmaceuticals has been revised higher from $16.40 to $16.80. Analysts point to stronger FY26 EBITDA guidance and recent target increases to $17 at multiple firms as support for the updated view.ナラティブ更新 • Mar 04
AMRX: 2026 EBITDA Outlook And Index Adds Will Shape Bullish Setup
Analysts have lifted their price target on Amneal Pharmaceuticals from $15.20 to $16.40, citing recent target hikes to $17 following solid Q4 results and 2026 guidance. The guidance highlights stronger EBITDA expectations despite more tempered revenue and margin assumptions, along with a higher future P/E of about 50x.ナラティブ更新 • Feb 17
AMRX: Affordable Medicines Theme And Index Adds Will Shape Measured 2026 Setup
Analysts have nudged their price targets on Amneal Pharmaceuticals higher, with the updated fair value estimate moving from $14.40 to $15.20. This change is supported by recent Street research highlighting continued interest in affordable medicines and the company's role in that theme.ナラティブ更新 • Feb 03
AMRX: Affordable Medicines Theme And Index Adds Will Shape Balanced 2026 Outlook
Analysts recently lifted their price target on Amneal Pharmaceuticals to $15 from $14, citing the company’s exposure to the affordable medicines theme as a key factor supporting their updated view. Analyst Commentary Recent commentary around Amneal Pharmaceuticals centers on its role in the affordable medicines theme and how that ties into expectations for execution and valuation heading into 2026.ナラティブ更新 • Jan 19
AMRX: Affordable Medicines Theme And Q3 Execution Will Guide Fairly Balanced Outlook
Narrative Update Analysts have lifted their implied price target on Amneal Pharmaceuticals to about $14.40 from $14, reflecting higher Street targets of up to $15 and supportive views on both the affordable medicines theme and the company’s recent Q3 results versus expectations. Analyst Commentary Recent research updates focus on Amneal Pharmaceuticals' role in affordable medicines and the implications of its latest quarterly results for valuation and execution.ナラティブ更新 • Jan 05
AMRX: Complex Generics Pipeline And Recent EPS Beat Will Shape Outlook
Analysts have nudged their fair value estimate for Amneal Pharmaceuticals higher to US$14.00 from US$13.80, reflecting updated price targets and recent quarterly results that came in ahead of prior Street EPS and revenue estimates. Analyst Commentary Bullish Takeaways Bullish analysts highlight that Q3 adjusted diluted EPS of US$0.17 came in ahead of prior Street expectations of US$0.14, which they see as a sign of solid execution against current earnings targets.ナラティブ更新 • Dec 13
AMRX: Complex Generics Approvals Will Support Future Earnings Upside
Analysts have modestly raised their price target on Amneal Pharmaceuticals to approximately $13.80 from about $13.50, reflecting better than expected earnings and revenue performance in the latest quarter. Analyst Commentary Bullish Takeaways Bullish analysts highlight the earnings beat, with adjusted diluted EPS exceeding Street expectations, as evidence that management is executing effectively on cost control and product mix.分析記事 • Nov 30
Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Despite an already strong run, Amneal Pharmaceuticals, Inc. ( NASDAQ:AMRX ) shares have been powering on, with a gain...ナラティブ更新 • Nov 29
AMRX: Continued Execution and Pipeline Milestones Will Support Balanced Outlook
Analysts have raised their price target for Amneal Pharmaceuticals from $11 to $13, citing the company's stronger than expected third-quarter results and improved earnings outlook. Analyst Commentary Following the recent quarterly results, analysts have weighed in on Amneal Pharmaceuticals with a focus on both the company's strengths and areas for caution as they consider the revised price target.ナラティブ更新 • Nov 15
AMRX: Sustained Outperformance Will Drive Future Earnings Confidence
Analysts have increased their price target for Amneal Pharmaceuticals from $11 to $13. They cite the company’s better-than-expected third-quarter earnings and revenue performance as the reason for this adjustment.分析記事 • Nov 14
Amneal Pharmaceuticals' (NASDAQ:AMRX) Earnings May Just Be The Starting Point
Amneal Pharmaceuticals, Inc. ( NASDAQ:AMRX ) recently posted some strong earnings, and the market responded positively...ナラティブ更新 • Nov 01
AMRX: Recent FDA Approvals And Pipeline Launches Will Drive Upside Momentum
Amneal Pharmaceuticals’ analyst price target has risen from $12.67 to $13.50, as analysts cite stronger revenue growth and an improved earnings outlook following the company’s recent results. Analyst Commentary Recent analyst updates indicate a mix of optimism and caution following Amneal Pharmaceuticals’ latest quarterly performance and forward guidance.ナラティブ更新 • Sep 17
Global Health Trends And Pipeline Launches Will Fuel Future Potential
Amneal Pharmaceuticals' consensus price target has been raised as analysts now assign a higher future P/E multiple, increasing their fair value estimate from $12.00 to $12.67. What's in the News Amneal received FDA approval for its sodium oxybate oral solution 500 mg/mL (generic for Xyrem) for narcolepsy, expanding beyond prior limited authorized generic distribution.分析記事 • Aug 08
Results: Amneal Pharmaceuticals, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
It's been a good week for Amneal Pharmaceuticals, Inc. ( NASDAQ:AMRX ) shareholders, because the company has just...
新しいナラティブ • Mar 22
CREXONT And Metsera Partnerships Will Capitalize On Growing GLP-1 Market
The strategic collaboration in GLP-1 therapies and biosimilars expands market reach, poised to drive significant future revenue growth.Seeking Alpha • Mar 19
Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued
Summary Amneal Pharmaceuticals, Inc. seems fundamentally undervalued, with a market cap significantly lower than peers despite similar revenue levels, suggesting potential for substantial stock price appreciation. The company reported strong 2024 financials, with revenues up 17% year-on-year, and forecasts continued growth in 2025, driven by diverse product segments. Amneal is reducing debt effectively, targeting a net debt to EBITDA ratio of 3.6-3.7 in 2025, enhancing financial stability and investor confidence. Key growth areas include biosimilars, specialty drugs like CREXONT, and the high-growth GLP-1 weight loss market, positioning AMRX stock for long-term success. Read the full article on Seeking AlphaCEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$157m |
| Mar 31 2026 | n/a | n/a | US$122m |
| Dec 31 2025 | US$9m | US$800k | US$72m |
| Sep 30 2025 | n/a | n/a | US$6m |
| Jun 30 2025 | n/a | n/a | US$3m |
| Mar 31 2025 | n/a | n/a | -US$13m |
| Dec 31 2024 | US$7m | US$788k | -US$117m |
| Sep 30 2024 | n/a | n/a | -US$184m |
| Jun 30 2024 | n/a | n/a | -US$175m |
| Mar 31 2024 | n/a | n/a | -US$169m |
| Dec 31 2023 | US$2m | US$750k | -US$84m |
| Sep 30 2023 | n/a | n/a | US$10m |
| Jun 30 2023 | n/a | n/a | -US$2m |
| Mar 31 2023 | n/a | n/a | -US$135m |
| Dec 31 2022 | US$5m | US$750k | -US$130m |
| Sep 30 2022 | n/a | n/a | -US$132m |
| Jun 30 2022 | n/a | n/a | -US$134m |
| Mar 31 2022 | n/a | n/a | US$2m |
| Dec 31 2021 | US$5m | US$724k | US$11m |
| Sep 30 2021 | n/a | n/a | US$14m |
| Jun 30 2021 | n/a | n/a | US$9m |
| Mar 31 2021 | n/a | n/a | -US$17m |
| Dec 31 2020 | US$2m | US$1 | US$91m |
| Sep 30 2020 | n/a | n/a | US$62m |
| Jun 30 2020 | n/a | n/a | -US$194m |
| Mar 31 2020 | n/a | n/a | -US$199m |
| Dec 31 2019 | US$446k | US$44k | -US$362m |
報酬と市場: Chiragの 総報酬 ($USD 8.69M ) は、 US市場 ($USD 8.29M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Chiragの報酬は過去 1 年間で 20% 以上増加しました。
CEO
Chirag Patel (59 yo)
21.6yrs
在職期間
US$8,691,745
報酬
Mr. Chirag K. Patel is Managing Trustee of Liberty Science Center, Inc. He is Co-Founder & Executive Chairman of Kashiv BioSciences, LLC. Mr. Patel has been Co-Chief Executive Officer, President and Direct...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Co-Founder | 21.6yrs | US$8.69m | 7.1% $ 418.4m | |
| Co-Founder | 24.6yrs | US$8.73m | 8.19% $ 482.6m | |
| Executive VP & CFO | 6.4yrs | US$3.29m | 0.14% $ 8.3m | |
| Executive VP | 4.6yrs | US$2.86m | 0.079% $ 4.6m | |
| Executive VP & Chief Human Resources Officer | 12.6yrs | US$2.73m | 0.13% $ 7.4m | |
| Executive VP and Chief Commercial Officer of Generics & Biosciences | 8.5yrs | US$3.02m | 0.13% $ 7.9m | |
| Head/VP of Investor Relations | no data | データなし | データなし | |
| Senior Vice President of Corporate Development | 3.6yrs | データなし | データなし | |
| Senior VP of Strategic Sourcing & Supply Management | 3.6yrs | データなし | データなし | |
| Chief Quality Officer | 7.6yrs | データなし | データなし | |
| Senior VP & Chief Scientific Officer of Generics | 6.6yrs | データなし | データなし | |
| Vice President & Head of Medical Affairs | no data | データなし | データなし |
7.1yrs
平均在職期間
56.5yo
平均年齢
経験豊富な経営陣: AMRXの経営陣は経験豊富で経験豊富です（平均在職期間は7.1年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Co-Founder | 21.6yrs | US$8.69m | 7.1% $ 418.4m | |
| Co-Founder | 24.6yrs | US$8.73m | 8.19% $ 482.6m | |
| Independent Chairman of the Board | 7yrs | US$472.63k | 0.26% $ 15.4m | |
| Independent Director | 8.3yrs | US$393.33k | 0.11% $ 6.2m | |
| Independent Director | 8.3yrs | US$401.03k | 0.10% $ 6.0m | |
| Independent Director | 6.7yrs | US$386.59k | 0.10% $ 5.9m | |
| Independent Director | 6.7yrs | US$413.91k | 0.11% $ 6.4m | |
| Director | 8.3yrs | US$363.61k | 0.52% $ 30.3m | |
| Independent Director | 4.1yrs | US$365.00k | 0.029% $ 1.7m | |
| Independent Director | 6.7yrs | US$434.59k | 0.082% $ 4.8m |
7.6yrs
平均在職期間
63yo
平均年齢
経験豊富なボード: AMRXの 取締役会 は 経験豊富 であると考えられます ( 7.6年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/06 17:50 |
| 終値 | 2026/08/06 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Amneal Pharmaceuticals, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。20
| アナリスト | 機関 |
|---|---|
| Glen Santangelo | Barclays |
| Gary Nachman | BMO Capital Markets Equity Research |
| David Buck | B. Riley Securities, Inc. |